该试验还发现,NGM621 耐受性良好,剂量高达 15 毫克,两次给药,没有安全信号,也没有严重的药物相关不良事件。 该药物目前处于 CATALINA 2 期研究 (NCT04465955) 中,240 名患者随机分配至每 4 或 8 周给药一次对比假治疗。
NGM621 is being further studied in GA in the ongoing Phase 2 CATALINA study (NCT04465955).David Aaron EichenbaumCharles C. WykoffVrinda HershbergerErin HenryHusam YounisPriya ChandraNeang LyNancy YuanAlex DePaoliInvestigative Ophthalmology & Visual Science...
Patients who met eligibility criteria were treated in a single ascending-dose phase (2 mg, 7.5 mg, and 15 mg) or received 2 doses of NGM621 (15 mg) 4 weeks apart in the multidose phase and were monitored for 12 weeks (85 days). Assessments included adverse events, best-corrected ...